Company Doesn't Expect Iclusig to Be Pulled From Market
Ariad Pharmaceuticals will discontinue a late-stage study of its leukemia drug Iclusig because of patient heart attacks, strokes and blocked blood vessels caused by blood clotting in study subjects receiving the treatment.
Ariad Pharmaceuticals Inc. will discontinue a late-stage study of its leukemia drug Iclusig because of patient heart attacks, strokes and blocked blood vessels caused by blood clotting in study subjects receiving the treatment. Ariad stopped enrolling new patients into the study last week after discovering an increased rate of serious side effects, but said existing
0 comments:
Post a Comment